开发一种新型治疗性抑制剂，可抑制脑内促炎细胞因子上调，减轻突触功能障碍和行为缺陷。
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
作者信息
Hu Wenhui, Ralay Ranaivo Hantamalala, Roy Saktimayee M, Behanna Heather A, Wing Laura K, Munoz Lenka, Guo Ling, Van Eldik Linda J, Watterson D Martin
机构信息
Center for Drug Discovery and Chemical Biology, Northwestern University, 303 E. Chicago Avenue, Mail Code W896, Chicago, IL 60611, USA.
出版信息
Bioorg Med Chem Lett. 2007 Jan 15;17(2):414-8. doi: 10.1016/j.bmcl.2006.10.028. Epub 2006 Oct 17.
Abstract
We report the development of a novel, aqueous-soluble, safe, small molecule, experimental therapeutic that suppresses injury-induced, proinflammatory cytokine increases in the brain, with resultant attenuation of synaptic protein biomarker loss and improvement in hippocampus-dependent behavioral deficits. A GMP production scheme for the active pharmaceutical ingredient, compound 17, is presented. The development and large-scale availability of this novel compound allow exploration of new, potentially disease-modifying, therapeutic approaches to CNS disorders.
摘要
我们报告了一种新型的、水溶性的、安全的小分子实验性治疗药物的研发情况，该药物可抑制脑损伤诱导的促炎细胞因子增加，从而减轻突触蛋白生物标志物的损失，并改善海马体依赖性行为缺陷。文中还介绍了活性药物成分化合物17的GMP生产方案。这种新型化合物的研发及其大规模可得性，为探索治疗中枢神经系统疾病的新的、可能具有疾病修饰作用的治疗方法提供了可能。
相似文献
1
Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits.
Bioorg Med Chem Lett. 2007 Jan 15;17(2):414-8. doi: 10.1016/j.bmcl.2006.10.028. Epub 2006 Oct 17.
2
A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model.
J Neuroinflammation. 2007 Sep 4;4:21. doi: 10.1186/1742-2094-4-21.
3
Early stage drug treatment that normalizes proinflammatory cytokine production attenuates synaptic dysfunction in a mouse model that exhibits age-dependent progression of Alzheimer's disease-related pathology.
J Neurosci. 2012 Jul 25;32(30):10201-10. doi: 10.1523/JNEUROSCI.1496-12.2012.
4
Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration.
J Neurosci. 2006 Jan 11;26(2):662-70. doi: 10.1523/JNEUROSCI.4652-05.2006.
5
S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice.
Pharmacol Biochem Behav. 2012 Jan;100(3):361-9. doi: 10.1016/j.pbb.2011.09.012. Epub 2011 Oct 2.
6
Regulation of proinflammatory cytokines gene expression by nociceptin/orphanin FQ in the spinal cord and the cultured astrocytes.
Neuroscience. 2007 Jan 5;144(1):275-85. doi: 10.1016/j.neuroscience.2006.09.016. Epub 2006 Oct 25.
7
Neflamapimod: Clinical Phase 2b-Ready Oral Small Molecule Inhibitor of p38α to Reverse Synaptic Dysfunction in Early Alzheimer's Disease.
J Prev Alzheimers Dis. 2017;4(4):273-278. doi: 10.14283/jpad.2017.41.
8
Selective inhibition of microglia-mediated neuroinflammation mitigates radiation-induced cognitive impairment.
Radiat Res. 2013 May;179(5):549-56. doi: 10.1667/RR3026.1. Epub 2013 Apr 5.
9
Attenuation of traumatic brain injury-induced cognitive impairment in mice by targeting increased cytokine levels with a small molecule experimental therapeutic.
J Neuroinflammation. 2015 Apr 10;12:69. doi: 10.1186/s12974-015-0289-5.
10
Enhancement of tripartite synapses as a potential therapeutic strategy for Alzheimer's disease: a preclinical study in rTg4510 mice.
Alzheimers Res Ther. 2019 Aug 23;11(1):75. doi: 10.1186/s13195-019-0530-z.
引用本文的文献
1
CNS-Active p38α MAPK Inhibitors for the Management of Neuroinflammatory Diseases: Medicinal Chemical Properties and Therapeutic Capabilities.
Mol Neurobiol. 2024 Jul;61(7):3911-3933. doi: 10.1007/s12035-023-03829-3. Epub 2023 Dec 2.
2
Clinical Trial Protocol for BEACH: A Phase 2a Study of MW189 in Patients with Acute Nontraumatic Intracerebral Hemorrhage.
Neurocrit Care. 2024 Apr;40(2):807-815. doi: 10.1007/s12028-023-01867-2. Epub 2023 Nov 2.
3
Partial Depletion of Microglia Attenuates Long-Term Potentiation Deficits following Repeated Blast Traumatic Brain Injury in Organotypic Hippocampal Slice Cultures.
J Neurotrauma. 2023 Mar;40(5-6):547-560. doi: 10.1089/neu.2022.0284. Epub 2022 Oct 12.
4
Neuroinflammation as a Potential Therapeutic Target in Alzheimer's Disease.
Clin Interv Aging. 2022 Apr 29;17:665-674. doi: 10.2147/CIA.S357558. eCollection 2022.
5
Therapeutic treatment with the anti-inflammatory drug candidate MW151 may partially reduce memory impairment and normalizes hippocampal metabolic markers in a mouse model of comorbid amyloid and vascular pathology.
PLoS One. 2022 Jan 26;17(1):e0262474. doi: 10.1371/journal.pone.0262474. eCollection 2022.
6
First-in-Human Studies of MW01-6-189WH, a Brain-Penetrant, Antineuroinflammatory Small-Molecule Drug Candidate: Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Studies in Healthy Adult Volunteers.
Clin Pharmacol Drug Dev. 2021 Feb;10(2):131-143. doi: 10.1002/cpdd.795. Epub 2020 Apr 7.
7
A Selective and Brain Penetrant p38αMAPK Inhibitor Candidate for Neurologic and Neuropsychiatric Disorders That Attenuates Neuroinflammation and Cognitive Dysfunction.
J Med Chem. 2019 Jun 13;62(11):5298-5311. doi: 10.1021/acs.jmedchem.9b00058. Epub 2019 Apr 23.
8
Distinct cytokine profiles in human brains resilient to Alzheimer's pathology.
Neurobiol Dis. 2019 Jan;121:327-337. doi: 10.1016/j.nbd.2018.10.009. Epub 2018 Oct 15.
9
New tricks for an ancient system: Physiological and pathological roles of complement in the CNS.
Mol Immunol. 2018 Oct;102:3-13. doi: 10.1016/j.molimm.2018.06.264. Epub 2018 Jun 27.
10
MW151 Inhibited IL-1β Levels after Traumatic Brain Injury with No Effect on Microglia Physiological Responses.
PLoS One. 2016 Feb 12;11(2):e0149451. doi: 10.1371/journal.pone.0149451. eCollection 2016.
本文引用的文献
1
Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
Nat Med. 2006 Sep;12(9):1005-15. doi: 10.1038/nm1484.
2
TNF-alpha modulation for treatment of Alzheimer's disease: a 6-month pilot study.
MedGenMed. 2006 Apr 26;8(2):25.
3
Tumor necrosis factor inhibitors for rheumatoid arthritis.
N Engl J Med. 2006 Aug 17;355(7):704-12. doi: 10.1056/NEJMct055183.
4
De novo and molecular target-independent discovery of orally bioavailable lead compounds for neurological disorders.
Curr Alzheimer Res. 2006 Jul;3(3):205-14. doi: 10.2174/156720506777632844.
5
Drug discovery: selecting the optimal approach.
Drug Discov Today. 2006 May;11(9-10):465-72. doi: 10.1016/j.drudis.2006.03.015.
6
Glia as a therapeutic target: selective suppression of human amyloid-beta-induced upregulation of brain proinflammatory cytokine production attenuates neurodegeneration.
J Neurosci. 2006 Jan 11;26(2):662-70. doi: 10.1523/JNEUROSCI.4652-05.2006.
7
Neuroinflammation: a potential therapeutic target.
Expert Opin Ther Targets. 2005 Oct;9(5):887-900. doi: 10.1517/14728222.9.5.887.
8
Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model.
Curr Alzheimer Res. 2005 Apr;2(2):197-205. doi: 10.2174/1567205053585828.
9
Glia and their cytokines in progression of neurodegeneration.
Neurobiol Aging. 2005 Mar;26(3):349-54. doi: 10.1016/j.neurobiolaging.2004.05.010.
10
Anti-TNF-alpha therapies: they are all the same (aren't they?).
Rheumatology (Oxford). 2005 Mar;44(3):271-3. doi: 10.1093/rheumatology/keh483. Epub 2004 Nov 23.
Zotero 插件